As we enter the winter flu season, embracing more innovative diagnostics at the point of care (POC) could play a vital role in helping to address the burden which influenza places on public health services.
Partner and patent attorney at intellectual property firm, Withers & Rogers, Dr Nicholas Jones, discusses why drug companies should continue to pursue new medical patents in the future, despite recent examples of legal disputes.
Amplexor’s VP of strategy for life sciences Romuald Braun asks how growing pressure on regulatory data is changing the way firms manage it and what is the best bet exploiting the transformation for the benefit of their own businesses?
New technologies are changing the way pharmaceutical supply chains operate. Here, Marc Herlant, Arthur D. Little, discusses how predictive analytics offers pharmaceutical manufacturers new supply chain capabilities.
With the cost of chronic diseases continuing to spiral and patients commonly failing to comply with medication, Chris Evans, West Pharmaceutical Services, explains why connected health could be the answer.
Chris Tozer, territory manager, UK, Ireland and Italy, Ivanti Supply Chain, looks at the complexities associated with the pharmaceutical supply chain and why legacy technology might be hindering efficiency.
Professor Carole Longson, chief scientific officer at the Association of the British Pharmaceutical Industry discusses the lack of female representation in STEM and why a woman in science is needed on the new £50 note.
